A Cost-Effectiveness Analysis of Fingolimod Versus Dimethyl Fumarate As A Second-Line Disease Modifying Treatment In Patients With Highly Active Relapsing-Remitting Multiple Sclerosis
Nov 1, 2015, 00:00
10.1016/j.jval.2015.09.2470
https://www.valueinhealthjournal.com/article/S1098-3015(15)04546-5/fulltext
Title :
A Cost-Effectiveness Analysis of Fingolimod Versus Dimethyl Fumarate As A Second-Line Disease Modifying Treatment In Patients With Highly Active Relapsing-Remitting Multiple Sclerosis
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(15)04546-5&doi=10.1016/j.jval.2015.09.2470
First page :
A758
Section Title :
Research Podium Presentations - Session 1 and Session 2
Open access? :
No
Section Order :
2348